| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03345535 |
| P698 | PubMed publication ID | 15816377 |
| P2093 | author name string | Renner U | |
| Holsboer F | |||
| Schneider HJ | |||
| Stalla GK | |||
| Keck ME | |||
| Paez-Pereda M | |||
| Tichomirowa MA | |||
| P2860 | cites work | Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor | Q24291179 |
| Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. | Q24534256 | ||
| Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors | Q24595282 | ||
| Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor | Q24629375 | ||
| Thyroid function in clinical subtypes of major depression: an exploratory study | Q24806204 | ||
| Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature | Q28189449 | ||
| Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study | Q28239287 | ||
| Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey | Q28258215 | ||
| An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial | Q28377083 | ||
| Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism | Q28506467 | ||
| Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation | Q28508582 | ||
| Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor | Q28584057 | ||
| Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety | Q29615160 | ||
| Serum immunoreactive-leptin concentrations in normal-weight and obese humans | Q29617230 | ||
| Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy | Q31925061 | ||
| Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock | Q33966738 | ||
| The corticosteroid receptor hypothesis of depression | Q34057906 | ||
| Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders | Q34241428 | ||
| Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects | Q43507948 | ||
| Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults | Q43807391 | ||
| CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression | Q43870990 | ||
| Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone | Q43975929 | ||
| Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist | Q44047416 | ||
| The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety | Q44111242 | ||
| Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins | Q44126284 | ||
| Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial | Q44265282 | ||
| Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. | Q44268849 | ||
| The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress | Q44285597 | ||
| Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. | Q44317343 | ||
| The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats | Q44370708 | ||
| Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test | Q44557831 | ||
| Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. | Q44584451 | ||
| Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation | Q44660833 | ||
| Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress | Q45197113 | ||
| Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency | Q46895060 | ||
| Pituitary size in depression | Q47433341 | ||
| Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load | Q47722791 | ||
| Psychoneuroendocrinology of depression. Growth hormone | Q47819031 | ||
| Growth hormone secretion during sleep in male depressed patients | Q48013391 | ||
| Stimulatory tests of growth hormone secretion in prepubertal major depression: depressed versus normal children | Q48091814 | ||
| The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders | Q48101414 | ||
| The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness | Q48102324 | ||
| Immunocytochemical evidence for direct synaptic connections between corticotrophin-releasing factor (CRF) and gonadotrophin-releasing hormone (GnRH)-containing neurons in the preoptic area of the rat. | Q48122005 | ||
| Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain | Q48223866 | ||
| The role of corticotropin-releasing factor in depression and anxiety disorders | Q48328352 | ||
| In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients | Q48420025 | ||
| Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. | Q48495413 | ||
| Relationship between pituitary responses to human corticotropin-releasing factor and thyrotropin-releasing hormone in depressives and normal controls | Q48506337 | ||
| Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene | Q48526900 | ||
| Plasma levels of arginine vasopressin elevated in patients with major depression | Q48609918 | ||
| The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats | Q48690628 | ||
| Growth hormone secretion in children and adolescents at high risk for major depressive disorder | Q48714033 | ||
| Hypothalamic-pituitary-thyroid-axis function in treatment resistant depression | Q48736630 | ||
| Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls | Q48822983 | ||
| The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus | Q48854070 | ||
| Profiles of spontaneous 24-hour and stimulated growth hormone secretion in male patients with endogenous depression | Q48868084 | ||
| Low leptin levels but normal body mass indices in patients with depression or schizophrenia | Q48887893 | ||
| Influence of Human Corticotropin-Releasing Hormone and Adrenocorticotropin upon Spontaneous Growth Hormone Secretion | Q48897001 | ||
| Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission | Q48914104 | ||
| Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients | Q48954318 | ||
| Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. | Q48956131 | ||
| The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness | Q49037226 | ||
| Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression | Q49151158 | ||
| Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test | Q49160010 | ||
| Plasma leptin in depressed patients and healthy controls. | Q50977100 | ||
| Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. | Q51394480 | ||
| DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. | Q52026391 | ||
| Effect of clonidine on growth hormone release in psychiatric patients and controls | Q52105073 | ||
| CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. | Q52128943 | ||
| Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. | Q55033164 | ||
| Psychoneuroendocrine research in depression | Q59619289 | ||
| Insulin-like growth factor I in depressed patients and controls | Q59619296 | ||
| Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects | Q67290947 | ||
| Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives | Q68353475 | ||
| Corticotropin-releasing hormone inhibition of growth hormone-releasing hormone-induced growth hormone release in man | Q68586041 | ||
| Recurrent depression is associated with a persistent reduction in sleep-related growth hormone secretion | Q68705893 | ||
| CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients | Q69878542 | ||
| Cerebrospinal fluid somatostatin and psychiatric illness | Q69878625 | ||
| Human corticotropin-releasing hormone in depression--correlation with thyrotropin secretion following thyrotropin-releasing hormone | Q70139701 | ||
| The GH response to clonidine in endogenous as compared with reactive depression | Q70808356 | ||
| Association of depression witk reduced heart rate variability in coronary artery disease | Q72064694 | ||
| Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients | Q72415584 | ||
| Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls | Q72934120 | ||
| Adrenal androgens and cortisol in major depression | Q72967178 | ||
| Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain | Q73072489 | ||
| Low growth hormone response to growth hormone-releasing hormone in child depression | Q73200035 | ||
| Glucocorticoid repression of gonadotropin-releasing hormone gene expression and secretion in morphologically distinct subpopulations of GT1-7 cells | Q73695036 | ||
| Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients | Q73888302 | ||
| Multihormonal responses to clonidine in patients with affective and psychotic symptoms | Q74154197 | ||
| [Leptin and psychiatric disorders] | Q74744547 | ||
| Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication | Q77164173 | ||
| Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients | Q77324973 | ||
| Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication | Q77379435 | ||
| Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment | Q77452507 | ||
| Testosterone, gonadotropin, and cortisol secretion in male patients with major depression | Q77878265 | ||
| Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects | Q34270532 | ||
| Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients | Q34419936 | ||
| Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress | Q34437169 | ||
| Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. | Q34471162 | ||
| Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression | Q34489874 | ||
| The hypothalamic-pituitary-gonadal axis in mood disorders | Q34677268 | ||
| Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress | Q34699486 | ||
| Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. | Q34740438 | ||
| Vasopressin as a target for antidepressant development: an assessment of the available evidence | Q34802216 | ||
| Genetic modification of corticosteroid receptor signalling: novel insights into pathophysiology and treatment strategies of human affective disorders | Q34930451 | ||
| Treatment of mood disorders | Q34982300 | ||
| Neurosteroids in depression: a review | Q34990942 | ||
| Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties | Q35037741 | ||
| Corticotropin-releasing hormone modulators and depression | Q35080784 | ||
| Plasticity and function of brain corticosteroid receptors during aging | Q37003185 | ||
| V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. | Q38294530 | ||
| Elevated nocturnal profiles of serum leptin in patients with depression | Q38330657 | ||
| Dehydroepiandrosterone (DHEA) treatment of depression | Q38457551 | ||
| Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. | Q38566515 | ||
| Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment | Q39412808 | ||
| Sex Differences and the Epidemiology of Depression | Q39617578 | ||
| Elevated corticosteroids as a possible cause of abnormal neuroendocrine function in depressive illness | Q39873499 | ||
| Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. | Q40394676 | ||
| Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression | Q40694754 | ||
| Women and mood disorders. Menarche to menopause | Q40816752 | ||
| The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment | Q40850649 | ||
| The impact of physiological stimuli on the expression of corticotropin-releasing hormone (CRH) and other neuropeptide genes | Q40935061 | ||
| Characterization of corticotropin-releasing factor receptor subtypes | Q40971035 | ||
| Antidepressants and hypothalamic-pituitary-adrenocortical regulation | Q41032512 | ||
| Adrenal gland enlargement in major depression. A computed tomographic study | Q41118597 | ||
| Corticotrophin-releasing factor receptors: from molecular biology to drug design | Q41293691 | ||
| Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims | Q41335204 | ||
| Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. | Q41340849 | ||
| Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis | Q41344771 | ||
| Glucocorticoid receptor-mediated repression of gonadotropin-releasing hormone promoter activity in GT1 hypothalamic cell lines | Q41483516 | ||
| Regulation of appetite and body weight | Q41535017 | ||
| Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients | Q41561553 | ||
| Double-blind treatment of major depression with dehydroepiandrosterone | Q41645579 | ||
| Thyroid hormones in depressive disorders: a reappraisal of clinical utility | Q41652995 | ||
| Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study | Q41671796 | ||
| Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery | Q41787226 | ||
| Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice | Q41878684 | ||
| Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin | Q42113446 | ||
| The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus | Q42280220 | ||
| Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications | Q42508360 | ||
| Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. | Q42514534 | ||
| Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity | Q42526331 | ||
| Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. | Q42649389 | ||
| Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. | Q42930123 | ||
| Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated | Q43504398 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 89-99 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Endocrine disturbances in depression | |
| P478 | volume | 28 |
| Q36316074 | A possible role for the endocannabinoid system in the neurobiology of depression |
| Q37405040 | Circuits Regulating Pleasure and Happiness-Mechanisms of Depression |
| Q36358110 | Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications |
| Q37662647 | Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance |
| Q36492123 | Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety |
| Q47615175 | Cranial electrotherapy stimulation affects mood state but not levels of peripheral neurotrophic factors or hypothalamic- pituitary-adrenal axis regulation |
| Q37038394 | Effect of Functionally Significant Deiodinase Single Nucleotide Polymorphisms on Drinking Behavior in Alcohol Dependence: An Exploratory Investigation |
| Q36524739 | Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis regulation in mice |
| Q38166682 | Harmful effects of functional hypercortisolism: a working hypothesis. |
| Q36950127 | Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study |
| Q51989422 | Hypoxic preconditioning prevents development of post-stress depressions in rats. |
| Q40322210 | Inhibition of corticotrophin-releasing hormone transcription by inducible cAMP-early repressor in the hypothalamic cell line, 4B. |
| Q28265397 | Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders |
| Q48307116 | Modulation of central glucocorticoid receptors in short- and long-term experimental hyperthyroidism. |
| Q47915265 | Neuropeptide y attenuates stress-induced bone loss through suppression of noradrenaline circuits |
| Q30494178 | Olfactory bulbectomy increases food intake and hypothalamic neuropeptide Y in obesity-prone but not obesity-resistant rats |
| Q47672598 | Permanent modification of neurohormone expression in the hypothalamus of rats on the model of learned helplessness |
| Q37738277 | Prolonged fasting as a method of mood enhancement in chronic pain syndromes: a review of clinical evidence and mechanisms |
| Q47303681 | Prolonged fasting in patients with chronic pain syndromes leads to late mood-enhancement not related to weight loss and fasting-induced leptin depletion |
| Q36297266 | Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action |
| Q48048867 | Seeking an objective diagnosis of depression |
| Q36511445 | Single nucleotide polymorphisms of NR3C1 gene and recurrent depressive disorder in population of Poland |
| Q39411491 | Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging |
| Q26786197 | The Effects of Calorie Restriction in Depression and Potential Mechanisms |
| Q30464954 | The GABAergic deficit hypothesis of major depressive disorder. |
| Q33887233 | The diagnosis of depression: current and emerging methods |
| Q33440537 | The possible use of hypoxic preconditioning for the prophylaxis of post-stress depressive episodes |
| Q30490519 | The role of corticotropin-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems |
| Q38089247 | The search for peripheral disease markers in psychiatry by genomic and proteomic approaches |
| Q30496339 | gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression |
Search more.